Trial · NCT04777331
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| DBT Period: Time to Confirmed Motor Progression Event Assessed by Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III | DBT Period: Placebo | 49.7 | 95% Confidence Interval 40.1 to 58.1 | weeks | |
| DBT Period: Time to Confirmed Motor Progression Event Assessed by Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III | DBT Period: Prasinezumab | 61.1 | 95% Confidence Interval 52.3 to 71.9 | weeks | |
| DBT Period: Time-to-worsening of Participant's Motor Function as Reported by the Participant in the Presence of a Confirmed Motor Progression Event | DBT Period: Placebo | 88.3 | 95% Confidence Interval 62.7 to 105.1 | weeks | |
| DBT Period: Time-to-worsening of Participant's Motor Function as Reported by the Participant in the Presence of a Confirmed Motor Progression Event | DBT Period: Prasinezumab | 112.1 | 95% Confidence Interval 81.1 to NA | weeks | |
| DBT Period: Time to Meaningful Worsening in Participant Global Impression of Change (PGI-C) Overall Disease Subscale | DBT Period: Placebo | 36.1 | 95% Confidence Interval 29.9 to 42.1 | weeks | |
| DBT Period: Time to Meaningful Worsening in Participant Global Impression of Change (PGI-C) Overall Disease Subscale | DBT Period: Prasinezumab | 44.4 | 95% Confidence Interval 38.1 to 52.1 | weeks | |
| DBT Period: Time to Meaningful Worsening in Clinician Global Impression of Change (CGI-C) Overall Disease Subscale | DBT Period: Placebo | 52.1 | 95% Confidence Interval 44.1 to 59.9 | weeks | |
| DBT Period: Time to Meaningful Worsening in Clinician Global Impression of Change (CGI-C) Overall Disease Subscale | DBT Period: Prasinezumab | 60.6 | 95% Confidence Interval 56.1 to 67.3 | weeks | |
| DBT Period: Time to Onset of Motor Complications as Assessed Through MDS-UPDRS Part IV | DBT Period: Placebo | 91.1 | 95% Confidence Interval 77.0 to 107.6 | weeks | |
| DBT Period: Time to Onset of Motor Complications as Assessed Through MDS-UPDRS Part IV | DBT Period: Prasinezumab | 100.1 | 95% Confidence Interval 81.0 to 117.1 | weeks | |
| DBT Period: Change in Motor Function From Baseline to Week 76, as Measured by the MDS-UPDRS Part III Score | DBT Period: Placebo | 4.00 | Standard Error 0.592 | Units on a scale | |
| DBT Period: Change in Motor Function From Baseline to Week 76, as Measured by the MDS-UPDRS Part III Score | DBT Period: Prasinezumab | 3.61 | Standard Error 0.597 | Units on a scale | |
| DBT Period: Change in Bradykinesia and Rigidity From Baseline to Week 76, as Measured by the MDS-UPDRS Part III Bradykinesia and Rigidity Subscore | DBT Period: Placebo | 2.77 | Standard Error 0.476 | Units on a scale | |
| DBT Period: Change in Bradykinesia and Rigidity From Baseline to Week 76, as Measured by the MDS-UPDRS Part III Bradykinesia and Rigidity Subscore | DBT Period: Prasinezumab | 2.85 | Standard Error 0.479 | Units on a scale | |
| DBT Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | DBT Period: Placebo | AEs | 260 | Participants | |
| DBT Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | DBT Period: Prasinezumab | AEs | 267 | Participants | |
| DBT Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | DBT Period: Placebo | SAEs | 34 | Participants | |
| DBT Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | DBT Period: Prasinezumab | SAEs | 34 | Participants | |
| DBT Period: Number of Participants With Adverse Events of Special Interest (AESI) | DBT Period: Placebo | 0 | Participants | ||
| DBT Period: Number of Participants With Adverse Events of Special Interest (AESI) | DBT Period: Prasinezumab | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04777331/results